Skip to main
BDTX

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is positioned for significant growth, as upcoming catalysts present potential value inflection points that could result in a substantial increase in stock value. The company's pipeline technology, particularly the drugs BDTX-4933 and BDTX-1535, demonstrates promising efficacy across a wide range of novel cancer mutations, including notable activity against actionable mutations like EGFR. Additionally, the lucrative opportunity within the first-line non-small cell lung cancer market, estimated to exceed $1 billion, reinforces expectations of positive financial performance in the near future.

Bears say

The financial outlook for Black Diamond Therapeutics Inc. is concerning due to the reduced confidence in the efficacy of its drug silevertinib, particularly in the context of the reported overall response rate (ORR) of 60%, which may not be replicable at lower doses. Additionally, the company's market capitalization of approximately $230 million reflects investor skepticism regarding silevertinib's competitiveness in the 1L EGFR-NCM patient population, compounded by high rates of treatment interruptions and adverse reactions. Overall, the disappointing clinical updates regarding the silevertinib's performance have led to a lack of confidence among investors, overshadowing other potential opportunities within the company's pipeline.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.